# Sorafenib Tosylate in Treating Patients With Metastatic, Locally Advanced, or Recurrent Medullary Thyroid Cancer

> **NCT00390325** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 21 (actual)

## Conditions studied

- Hereditary Thyroid Gland Medullary Carcinoma
- Locally Advanced Thyroid Gland Medullary Carcinoma
- Multiple Endocrine Neoplasia Type 2A
- Multiple Endocrine Neoplasia Type 2B
- Recurrent Thyroid Gland Medullary Carcinoma
- Sporadic Thyroid Gland Medullary Carcinoma
- Stage III Thyroid Gland Medullary Carcinoma AJCC v7
- Stage IV Thyroid Gland Medullary Carcinoma AJCC v7
- Stage IVA Thyroid Gland Medullary Carcinoma AJCC v7
- Stage IVB Thyroid Gland Medullary Carcinoma AJCC v7
- Stage IVC Thyroid Gland Medullary Carcinoma AJCC v7

## Interventions

- **DRUG:** Sorafenib Tosylate

## Key facts

- **NCT ID:** NCT00390325
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-11-03
- **Primary completion:** 2017-01-30
- **Final completion:** 2022-12-22
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2024-02-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00390325

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00390325, "Sorafenib Tosylate in Treating Patients With Metastatic, Locally Advanced, or Recurrent Medullary Thyroid Cancer". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT00390325. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*